The Filing Desk

LeMaitre Vascular vs PROCEPT BioRobotics

LeMaitre Vascular LMAT · PROCEPT BioRobotics PRCT · Health Care Equipment

PROCEPT BioRobotics reported revenue of $308 million in fiscal 2025, 1.2 times LeMaitre Vascular's $250 million in fiscal 2025. LeMaitre Vascular's revenue grew 13.5% in its latest year, and PROCEPT BioRobotics' grew 37.2%. LeMaitre Vascular had an operating margin of 27.2%, against -33.7% at PROCEPT BioRobotics. Free cash flow was $74 million at LeMaitre Vascular and −$58 million at PROCEPT BioRobotics.

Side by side

LeMaitre VascularPROCEPT BioRobotics
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$250M$308M
Revenue growth13.5%37.2%
Revenue growth a year, last 5 years14.0%109.1%
Gross margin71.5%63.7%
Operating margin27.2%−33.7%
Net margin23.1%−31.0%
Free cash flow$74M−$58M
Free cash flow margin29.8%−18.9%
Return on capital25.5%−65.4%
Net debt to EBITDA−2.4x—
Dividends and buybacks$20M$0M
Change in diluted share count0.7%6.6%
Last close$78.29$23.80
P/E at the last close28.5×—
Insider trades, last 12 monthssold $30.0 million—
Piotroski F-score5 of 95 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
LeMaitre VascularPROCEPT BioRobotics
Operating margin
Percent of revenue
LeMaitre VascularPROCEPT BioRobotics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
LeMaitre VascularPROCEPT BioRobotics

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the LeMaitre Vascular and PROCEPT BioRobotics pages.